Table 2.
Selectivity index of ruthenium complexes containing heterocyclic thioamidates.
| Cancer cells | Noncancerous cells | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBMCs | MRC-5 | |||||||||||
| (1) | (2) | (3) | (4) | DOX | OXA | (1) | (2) | (3) | (4) | DOX | OXA | |
| HepG2 | 1.0 | 1.4 | 1.8 | 1.6 | 8.3 | 4.3 | 0.9 | 0.8 | 0.7 | N.d. | 1.3 | 0.7 |
| HL-60 | 1.4 | 2.4 | 2.6 | 2.6 | 12.5 | 15.7 | 1.2 | 1.5 | 1.1 | N.d. | 2.0 | 2.5 |
| K-562 | 1.9 | 2.9 | 2.8 | 1.8 | 2.8 | 9.4 | 1.6 | 1.8 | 1.2 | N.d. | 0.4 | 1.5 |
| B16-F10 | 1.5 | 2.0 | 3.3 | 1.3 | 12.5 | 4.3 | 1.3 | 1.2 | 1.4 | N.d. | 2.0 | 0.7 |
| MCF-7 | N.d. | 0.4 | 1.5 | N.d. | 6.3 | 1.6 | N.d. | 0.2 | 0.6 | N.d. | 1.0 | 0.3 |
| HCT116 | N.d. | 1.0 | 2.2 | N.d. | 8.3 | 2.3 | N.d. | 0.6 | 0.9 | N.d. | 1.3 | 0.4 |
| HSC-3 | N.d. | 1.2 | 2.5 | N.d. | 5.0 | 2.9 | N.d. | 0.7 | 1.0 | N.d. | 0.8 | 0.5 |
| SCC-4 | N.d. | 0.7 | 2.8 | N.d. | 0.6 | 1.2 | N.d. | 0.4 | 1.1 | N.d. | 0.1 | 0.2 |
The selectivity index (SI) of each complex was calculated using the following formula: SI = IC50 [noncancerous cells]/IC50 [cancer cells]. Cancer cells: HepG2 (human hepatocellular carcinoma); HL-60 (human acute promyelocytic leukemia); K-562 (human chronic myelogenous leukemia); B16-F10 (mouse melanoma); MCF-7 (human breast adenocarcinoma); HCT116 (human colon carcinoma); HSC-3 (human oral squamous cell carcinoma); and SCC-4 (human oral squamous cell carcinoma). Noncancerous cells: PBMCs (human peripheral blood mononuclear cells) and MRC-5 (human lung fibroblast). Doxorubicin (DOX) and oxaliplatin (OXA) were used as the positive controls. N.d. = Not determined.